Nieuws
Voor Nieuwsberichten, klik op onderstaande titels.
- Medische Technologie meets Life Science
- QPS Announces the Acquisition of Xendo Drug Development
- Xendo Drug Development, a leading position in (LC-)ICP-MS bioanalysis for over 7 years
- Xendo announces Partnership with QPS
- Xendo completes clinical part of Phase I study with DBS
- Xendo Drug Development is introducing UHPLC in the bioanalytical laboratories
- Phase I study with Dried Blood Spot technology for clinical sampling and bioanalysis
- high-throughput screening for culture medium optimization
- Strengere controle gezondheidszorg door IGZ / Dutch inspection tightens control
- New organization chart for Xendo
- Xendo's Integrated Drug Development concept accelerates biopharmaceutical development projects
- Immulite 2000 Analyzer
- Immunogenicity analysis and multiplex biomarker assays with new ECL equipment at Xendo
- Full clinical research services now offered
- Xendo's Bioanalysis and Drug Metabolism introduces new LIMS
- Disposables Reach Out to New Markets
- TI Pharma project on metabolic stability of NCE's takes off
- Xendo joins the Ride for the Roses
- Xendo CTM's director interviewed by C2W
- New Managing Director in Denmark
- The bisphosphonates bioanalytical challenge – Xendo’s answer: the risedronate case
- Focus Scandinavian activities
- Xendo CTM, a new life science company in The Netherlands
- Business Management services expanded
- Clinical pharmacology of chiral compounds – an expertise of Xendo
- GMP status van Nederlandse ziekenhuizen
- Xendo Newsletter special edition on bioanalysis and biomarkers - out now!
- Xendo conducts human microdosing (human phase 0) study for Biofrontera AG
- On-line clinical studies – LPS challenge testing
- On-line clinical studies – full integration of CPrU and bioanalysis
- Biotech News interview with Koos Koops and Ard Tijsterman
- Xendo partner in Top Institute Pharma
